Skip to main content

Home/ Dr. Goodyear/ Group items tagged VDR

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Vitamin D is associated with testosterone and hypogonadism in Chinese men: Results from... - 0 views

www.ncbi.nlm.nih.gov/...PMC4504177

vitamin d male hormones low T low Testosterone Testosterone

shared by Nathan Goodyear on 09 Jan 17 - No Cached
  • lower 25(OH)D level was significantly associated with lower total T, E2, SHBG, LH and FSH levels after adjusting for age, residence area, economic status and current smoker
  • association between 25(OH)D status and hypogonadism in Chinese men and confirms that this relationship is present in a large population
  • VDR knockout mutant mice showed gonadal insufficiencies
  • ...6 more annotations...
  • High LH and FSH levels in the male mice indicated hypergonadotropic hypogonadism
  • Another mouse study reported a tendency towards low testosterone/LH ratio and Leydig cell hyperplasia in VDR null mice
  • The serum testosterone levels could increase to normal values in vitamin D-deficient rats replete with vitamin D
  • VDR knockout mice had decreased sperm count, reduced sperm motility, and histological abnormality of the testis
  • vitamin D supplementation increases testosterone levels in non-diabetic subjects
  • The data from the European Male Ageing Study [9] indicated that 25(OH)D is positively associated with total T
  • Nathan Goodyear on 09 Jan 17
     
    Study of 713 Chinese men finds a correlation between low vitamin D and low total Testosterone.
Nathan Goodyear

Regulation of CYP3A4 and CYP3A5 expressi... [Mol Cell Endocrinol. 2012] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...22939842

VDR vitamin D receptors CYP3A4

shared by Nathan Goodyear on 29 Nov 13 - No Cached
  • Nathan Goodyear on 29 Nov 13
     
    Vitamin D receptors found to increase CYP3A4 and CYP3A5 expression.  This has impacts on hormone metabolism.  According to the results, low vitamin D will result in decreased clearance of hormone through particularily through the CYP3A4 pathway.
Nathan Goodyear

A novel perspective for Alzheimer's disease... [J Alzheimers Dis. 2011] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...20966550

alzheimer disease alzheimers amyloid-beta vitamin D vitamin d VDR receptor

shared by Nathan Goodyear on 04 Jun 14 - No Cached
  • Nathan Goodyear on 04 Jun 14
     
    Alzheimer's model finds that amyloid-beta supresses vitamin D receptor.  This study found that vitamin D therapy protected neurons by up regulating vitamin D receptors.  This prevented cytotoxicity and cell death.
Nathan Goodyear

The impact of vitamin D in breast cancer: genomics, pathways, metabolism - 0 views

www.ncbi.nlm.nih.gov/...PMC4055997

vitamin D vitamin D VDR cancer

shared by Nathan Goodyear on 07 Jul 14 - No Cached
  • Nathan Goodyear on 07 Jul 14
     
    Good review of data on vitamin D, Vitamin D receptors and cancer risk.  Studies have shown that low Vitamin D levels are associated with increased cancer risk and that higher vitamin D levels are associated with reduced cancer risk.  The ability to fully map out vitamin Ds role in the physiology is probably difficult due to the heterogeneity of cancer development and physiology.
Nathan Goodyear

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside - 0 views

www.ncbi.nlm.nih.gov/...PMC5686300

nagalase Gc-MAF cancer

shared by Nathan Goodyear on 29 Jan 18 - No Cached
  • MAF precursor activity has also been lost or reduced after Gc-globulin treatment in some cancer cell lines
  • This appears to result from the deglycosylated ɑ-N-acetylgalactosaminidase (nagalase) secreted from cancerous cells
  • Nagalase has been detected in many cancer patients, but not in healthy individuals
  • ...31 more annotations...
  • Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
  • It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
  • The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
  • It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
  • The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
  • Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
  • Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
  • The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
  • Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
  • Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
  • It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
  • Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
  • Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
  • weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
  • this treatment has been suggested for non-anemic patients
  • Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
  • Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
  • In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
  • individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
  • Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
  • Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
  • There is also evidence that confirms the tumoricidal role of Gc-MAF via Fc-receptor mediation
  • It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
  • it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
  • The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
  • Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
  • Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
  • It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
  • inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
  • macrophages highly-activated by the addition of Gc-MAF can show tumoricidal activity
  • Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
  • Nathan Goodyear on 29 Jan 18
     
    great review on Gc-MAF in cancer.  An increase in nagalase blocks Gc-protein to Gc-MAF activity leaving the host immune system compromised.
1 - 5 of 5
Showing 20▼ items per page